Page last updated: 2024-12-09

thionicotinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID737155
CHEMBL ID3741182
SCHEMBL ID259899
SCHEMBL ID8692651
MeSH IDM0192685

Synonyms (46)

Synonym
HMS1760C13
BB 0258227
3-pyridylthioformamide
nsc 18336
brn 0109593
einecs 225-036-6
3-pyridinecarbothioamide
thio-3-pyridinecarboxamide
nicotinamide, thio-
3-thioamidopyridine
nsc-18336
nsc18336
nicotinothioamide
4621-66-3
thionicotinamide
3-thiocarbamoylpyridine
3-pyridinethiocarboxamide
amino-3-pyridylmethane-1-thione
pyridine-3-carbothioamide
inchi=1/c6h6n2s/c7-6(9)5-2-1-3-8-4-5/h1-4h,(h2,7,9
STK400207
3-pyridylthiocarboxamide
T0765
AKOS000119582
A827011
pyridine-3-carbothioic acid amide
5-22-02-00187 (beilstein handbook reference)
6a0hxx0753 ,
unii-6a0hxx0753
FT-0635375
3-(aminothiocarbonyl)pyridine
SCHEMBL259899
DTXSID9063536
SCHEMBL8692651
bdbm60920
CHEMBL3741182
F0001-1251
mfcd00006399
AS-11018
AMY13354
EN300-17569
SY026920
Q27264385
M58 ,
CS-0072201
Z56960184

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" At 24 hours from dosing about 35% of the dose had been excreted as inorganic sulphate and 20."( The metabolism of thionicotinamide in the rat.
Ruse, MJ; Waring, RH, 1991
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)7.50000.03403.987110.0000AID1265266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusKic4.30000.70002.30004.3000AID1265268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
nicotinamide metabolic processNicotinamide N-methyltransferaseHomo sapiens (human)
response to xenobiotic stimulusNicotinamide N-methyltransferaseHomo sapiens (human)
response to organonitrogen compoundNicotinamide N-methyltransferaseHomo sapiens (human)
animal organ regenerationNicotinamide N-methyltransferaseHomo sapiens (human)
methylationNicotinamide N-methyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of gluconeogenesisNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of protein deacetylationNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
nicotinamide N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
pyridine N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1802032NNMT Enzymatic Activity Assay from Article 10.1021/acs.biochem.6b00733: \\A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.
AID1265271Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 10 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265272Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 20 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1865595Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
(-)-Epigallocatechin Gallate is a Noncompetitive Inhibitor of NAD Kinase.
AID1265266Inhibition of mushroom tyrosinase using L-tyrosine as substrate2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1865594Cytotoxicity against human CCRF-CEM cells assessed as inhibition of cell growth2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
(-)-Epigallocatechin Gallate is a Noncompetitive Inhibitor of NAD Kinase.
AID1265269Binding affinity to mushroom tyrosinase assessed as fluorescence quenching2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1865596Cytotoxicity against human RL cells assessed as inhibition of cell growth2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
(-)-Epigallocatechin Gallate is a Noncompetitive Inhibitor of NAD Kinase.
AID1265270Cytotoxicity against mouse B16F10 cells assessed as cell survival at 50 uM after 48 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265273Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 50 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1865597Cytotoxicity against human C85 cells assessed as inhibition of cell growth2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
(-)-Epigallocatechin Gallate is a Noncompetitive Inhibitor of NAD Kinase.
AID1265268Non-competitive inhibition of mushroom tyrosinase using L-tyrosine as substrate by Lineweaver-Burk plots analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265274Inhibition of tyrosinase in mouse B16F10 cell lysates using DOPA as substrate relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's3 (18.75)18.2507
2000's4 (25.00)29.6817
2010's7 (43.75)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.58 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]